Literature DB >> 11724160

Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.

.   

Abstract

Ciprofloxacin or doxycycline is recommended for antimicrobial prophylaxis and treatment of adults and children with Bacillus anthracis infection associated with the recent bioterrorist attacks in the United States. Amoxicillin is an option for antimicrobial prophylaxis for children and pregnant women and to complete treatment of cutaneous disease when B. anthracis is susceptible to penicillin, as is the case in the recent attacks. Use of ciprofloxacin or doxycycline might be associated with adverse effects in children, and liquid formulations of these drugs are not widely available. This notice provides further information about prophylaxis and treatment of children and breastfeeding mothers, including the use of amoxicillin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724160

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  Inhibition of Bacillus anthracis spore outgrowth by nisin.

Authors:  Ian M Gut; Angela M Prouty; Jimmy D Ballard; Wilfred A van der Donk; Steven R Blanke
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.

Authors:  M Jasmine Mohammed; Chung K Marston; Tanja Popovic; Robbin S Weyant; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.

Authors:  Peter C B Turnbull; Nicky M Sirianni; Carlos I LeBron; Marian N Samaan; Felicia N Sutton; Anatalio E Reyes; Leonard F Peruski
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax.

Authors:  David M Bell; Phyllis E Kozarsky; David S Stephens
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

5.  Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Authors:  Patrick Grohs; Isabelle Podglajen; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Adverse events associated with prolonged antibiotic use.

Authors:  Sharon B Meropol; K Arnold Chan; Zhen Chen; Jonathan A Finkelstein; Sean Hennessy; Ebbing Lautenbach; Richard Platt; Stephanie D Schech; Deborah Shatin; Joshua P Metlay
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-05       Impact factor: 2.890

7.  Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon M Dyer; Patricia S Gideon; Kathleen S Hall; Lisa A Kaltenbach; Wayne A Ray
Journal:  Paediatr Perinat Epidemiol       Date:  2009-01       Impact factor: 3.980

8.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response.

Authors:  Vincent P Hsu; Susan L Lukacs; Thomas Handzel; James Hayslett; Scott Harper; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Conrad P Quinn; Rima Khabbaz; Ali S Khan; Gregory Martin; John Eisold; Anne Schuchat; Rana A Hajjeh
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

9.  Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001.

Authors:  Michael E Bales; Andrew L Dannenberg; Philip S Brachman; Arnold F Kaufmann; Peter C Klatsky; David A Ashford
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  Public health in the time of bioterrorism.

Authors:  Bradley A Perkins; Tanja Popovic; Kevin Yeskey
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.